title: Anti-platelet therapy: ADP receptor antagonists.
abstract: The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.
authors.affiliation: Division of Cardiovascular Medicine, School of Clinical Sciences, University of Nottingham, Nottingham, UK. ydw@doctors.org.uk
authors.forename: Yanushi Dullewe
authors.initials: YD
authors.lastname: Wijeyeratne
authors.forename: Stan
authors.initials: S
authors.lastname: Heptinstall
mesh_terms: D001792:Blood Platelets / Q000187:drug effects; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology*; D013927:Thrombosis / Q000517:prevention & control
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists